

Nuclear M-CSF Accelerates DNA Replication and Cell Proliferation in HeLa Human Cervical Cancer Cells

Jian Tu¹, Ting Xiong¹, Shujing Teng¹, Zhigang Zhou², Xiaoyong Lei¹, Shengsong Tang^{1,*}

¹Department of Pharmacology, University of South China, Hengyang, China

²Department of Anesthesiology, University of South China, Hengyang, China

Email address:

tangss111@aliyun.com (Shengsong Tang)

*Corresponding author

To cite this article:

Jian Tu, Ting Xiong, Shujing Teng, Zhigang Zhou, Xiaoyong Lei, Shengsong Tang. Nuclear M-CSF Accelerates DNA Replication and Cell Proliferation in HeLa Human Cervical Cancer Cells. *Cell Biology*. Vol. 5, No. 1, 2017, pp. 1-7. doi: 10.11648/j.cb.20170501.11

Received: January 31, 2017; **Accepted:** February 20, 2017; **Published:** March 4, 2017

Abstract: Macrophage colony-stimulating factor (M-CSF), also named colony-stimulating factor-1 (CSF-1), plays an important role in the process of proliferation and differentiation of the monocyte/macrophage lineage cells. Commonly, it is not easy to measure the expression of cellular M-CSF. However, recent studies have shown that M-CSF can be expressed at a high level in the cytoplasm and nuclei of some kinds of malignant tumors, which related to the poor prognosis. To explore the role and mechanism of nuclear M-CSF, in the present study we constructed the pCMV/nuc/M-CSF vector and transfected it into human HeLa nuclei. The results from our previous study indicated, M-CSF was stably expressed in HeLa nuclei, which were used as a model to determine the nuclear effects of M-CSF. There was a higher percentage of replicating nuclei in the transfected pCMV/nuc/M-CSF HeLa cells both in phase G1 and S. According to the data from the cell doubling time, antisense oligonucleotides and the experiments of the transplanted tumor in nude mice, nuclear M-CSF could promote the cell proliferation of HeLa cells both *in vivo* and *in vitro*. In conclusion, nuclear M-CSF could accelerate DNA replication and cell proliferation of cervical carcinoma.

Keywords: Microphage Colony-Stimulating Factor (M-CSF), HeLa Nuclei, DNA Replication, Cell Proliferation

1. Introduction

Cervical cancer is one of the most frequent diseases of the reproductive organs and its morbidity rate is constantly increasing. The development of cervical cancer seems to be highly associated with human papillomavirus (HPV) infection [1]. Although HPV is the major etiological agent of cervical cancer, yet the viral infection alone is not sufficient for cancer progression [2]. Ławicki et al. shows that different tumor markers may also be useful in the diagnosis of cervical cancer [3], including squamous cell carcinoma antigen (SCC-Ag), tissue polypeptide antigen (TPA), as well as some cytokines such as vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF), and so on. It has been shown that HPV enhanced expression of IL-1 β and IL-8, while G-CSF and M-CSF did not change. M-CSF, also called colony-stimulating factor-1 (CSF-1), is important in

controlling the survival, proliferation and differentiation of the monocyte/macrophage lineage cells both *in vivo* and *in vitro* [4]. As an extracellular signaling molecule, M-CSF swims in body fluids in normal physiological conditions. It is binding with the extracellular matrix or exists on the surface of cell membrane only during the embryonic period. When the function process is completed, M-CSF will be endocytosised and degraded in the cells. Therefore, it is not easy to measure the expression of cellular M-CSF [5, 6]. Encoded by a single gene, M-CSF contains five mature alternative transcripts. Under pathological conditions, there are at least three isoforms of M-CSF [7]: soluble M-CSF (s-M-CSF), membrane-bound M-CSF (m-M-CSF) and proteglycan-bound M-CSF (PG-M-CSF), which have been generated from these transcripts through co- and post-translational modifications. Different kinds of M-CSF isoforms are found in different cell types and under various conditions of stimulation.

Recently, the potential role and mechanism of cellular

M-CSF have been focused in leukemia, cervical cancer, endometrial carcinomas and breast cancer, and so on [8-11]. The data of Nameer Kirma showed the induction of cellular M-CSF and its receptor (c-fms) in cervical carcinomas and suggest that blocking CSF-1/c-fms might be a viable therapeutic strategy in the treatment of cervical cancer [12]. Moreover, intracellular M-CSF (including cytosol or nuclear M-CSF) was also identified pathologically in the cell lines of leukemia, breast cancer and Hepatocellular Carcinoma (HCC)[13-15]. Interestingly, nuclear M-CSF (nM-CSF) was found only in some tumor cells other than normal cells. The result of pathological analysis on nM-CSF showed that, the appearance of nM-CSF suggested poor prognosis and increased metastasis tendency in some carcinomas [16, 17]. But the function and mechanism of nM-CSF have not been elucidated. To further explore the role and mechanism of nM-CSF, we have constructed pCMV/nuc/M-CSF vector and transfected it into human HeLa nuclei [18].

2. Method

2.1. Materials

E. coli DH5 α was kept in our laboratory, pCMV/myc/nuc was purchased from Invitrogen (Carlsbad, CA), and pET32c+/M-CSF was kindly provided by Doctor Cao ZY. Plasmid pCMV/nuc/M-CSF was described previously [19]. HeLa cells were purchased from Zhongshan Medical College cell bank (Guangzhou, China).

2.2. Cell Culture and Transfection

A total of 1×10^5 HeLa cells were seeded into the 24-well tissue culture plate. The cell monolayer was washed with pre-warmed sterile phosphate-buffered saline (PBS) the next day (when the cells were 50%–80% confluent). The cells were transfected by using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. The cells were placed in the selection medium containing different concentration (200, 400, 600, 800, or 1000 $\mu\text{g}/\text{mL}$) of G418 (Invitrogen, Carlsbad, CA). Fourteen days later, the cells were harvested for analysis.

2.3. DNA Replication Assessment *in Vivo* Using Bromo-Deoxyuridine (BrdU)

Transfected and controlled HeLa cells ($2-5 \times 10^5$ cells) were seeded into the 6-well tissue culture plate (with a 24 mm \times 24 mm coverslip inside). After 48 h, the medium was replaced with fresh medium containing 50 μM BrdU, and the cells were cultured at 37°C for 30 min. Then, the cells were washed with ice-cold PBS, fixed with 4% formaldehyde at room temperature for 10 min, washed with PBS twice, and permeabilized with 0.5% TritonX-100 in PBS on ice for 5-10 min. After being washed with PBS and rinsed with sterilized distilled water, the cells (on the coverslip) were lysed by incubation with 2 mol/L HCl at 37°C for 1 h and then neutralized with 0.1 mol/L Na₂B₄O₇. The coverslips were then incubated with anti-BrdU mAb (diluted at 1:200) in

0.5%BSA/0.1%Tween20/PBS overnight. The coverslips were washed with the BSA/Tween/PBS solution, and incubated with FITC-conjugated secondary antibody (diluted at 1:50) for 2 h at room temperature. In a dark room, the coverslips were washed with PBS, incubated with 20 $\mu\text{g}/\text{mL}$ propidium iodide at room temperature for 3 min and then examined by fluorescence microscopy. Replication *in vivo* was analyzed by using BrdU. After the absorbing of BrdU, BrdUTP was produced as phosphorylation. The precursor BrdUTP could be incorporated to DNA instead of dTTP. Then, with anti-BrdU monoclonal primary antibody and FITC marked secondary antibody tested, nuclei in duplicate present green fluorescent. After Propidium Iodide (PI) redyeing, the nuclei were red.

2.4. Mammalian Cell-Free DNA Replication System *in Vitro*

2.4.1. Cell Synchronization

The cells were synchronized in block by using a culture medium containing 2.5 mM thymidine (Sigma) according to the methods previously described [20]. The process was verified by flow cytometry.

2.4.2. Preparation of Nuclei and Cell-Free Extracts

The cells were washed twice with ice-cold hypotonic buffer (20 mM potassium-HEPES [pH 7.8], 5 mM potassium acetate, 0.5 mM MgCl₂, and 0.5 mM DTT). All subsequent steps were carried out at 4°C. The cells were allowed to swell for 10 min in 20 mL hypotonic buffer per plate and the excess buffer was removed. At this stage, mitotic cells were lost because they detached from the substratum under hypotonic conditions. The interphase cells still attaching to the substratum that were scraped off the plates and disrupted with 25 strokes in a dounce homogenizer (Wheaton) using a loose-fitting pestle. The nuclei were pelleted at 1,700g for 5 min. The supernatant was used to prepare the cytosolic extract. Pelleted nuclei were resuspended and washed three times in PBS and finally pelleted at 1,700g for 5 min. The excess supernatant was removed, and the pelleted nuclei were resuspended in the residual volume. The concentration of nuclei were determined with a hemocytometer.

2.4.3. DNA Synthesis *in Vitro*

Reactions were carried out in 50 μL of a buffered nucleotide mix (yielding final concentrations of 40 mM K-HEPES [pH 7.8]; 7 mM MgCl₂; 3 mM ATP; 0.1 mM of each of GTP, CTP, UTP; 3 mM ATP; 0.25 μM biotin-16-dUTP; 0.5 mM DTT; 40 mM creatine phosphate; and 5 μg phosphocreatine kinase). Nuclei (1×10^5 per reaction) were mixed with the buffered nucleotide mix on ice and the reaction was started by transferring the tube to 37°C for 2 h. After centrifugation at 100g for 5 min and washed with PBS twice, the nuclei were transferred onto the coverslips precoated with Poly-L-Lysine. The coverslips were fixed with 4% formaldehyde at room temperature for 10 min, washed with PBS twice, and then permeabilized with 0.5%TritonX-100/PBS on ice for 5 to 10 min. The coverslips were washed with PBS twice and incubated with FITC-conjugated anti-avidin (diluted at 1: 64 with 1%BSA/PBS) for 2 h at room temperature. In the dark

room, the coverslips were washed with PBS and examined by fluorescence microscopy.

2.5. Cell Kinetic Analysis

2.5.1. Counting the Cell Doubling Time

The cells were harvested and counted continuously from the 1st to 7th day to take averaging by three wells each time and three times each well. The calculation formula of the doubling time was as follows: Doubling time (d) = [TIME (end) - TIME (begin)] / Log₂ [Cell concentration (end) / Cell concentration (begin)].

2.5.2. Cell Proliferation Assay

The cell proliferative rate was determined by Methylthiazolyl-diphenyl-tetrazolium bromide (MTT) assay. The three kinds of HeLa cells (1×10^4 per well) were cultured in 96-well plates. Thereafter, 20 μ L MTT solution was added to each well. After continued incubation for 4 h, the supernatant was discarded and 200 μ L DMSO was added. Once the blue crystals were dissolved, the optical density (OD) was measured at 490 nm using a plate microreader (Tecan Spectra, Wetzlar, Germany). The experiments were performed in triplicate. The proliferation rate was determined using the following formula: Cell proliferation (%) = OD of the experimental samples / OD of the control \times 100% (n=3, mean \pm SD).

2.5.3. M-CSF-specific Antisense Oligonucleotide

M-CSF-specific antisense oligonucleotide (nucleotide sulfur generation modified) was 5'-gcgccccgcgctcat-3' and random fragment contrast (nucleotide sulfur generation modified) sequence was 5'-cgcacgctgctgctcg-3', synthesized by the Shanghai biological engineering co., LTD. The cell concentration was adjusted for 5×10^4 cells/mL to vaccinate 96-well plates, each well 180 μ L. With RPMI1640 medium dissolved, (1, 3, 5, 7, 9 nmol/L) antisense oligonucleotides were joined every well for 44 h, and 20 μ L MTT (5 mg/mL) was added to cultivate for 4 h, then 200 μ L DMSO was added. The inhibitory rate of M-CSF-specific antisense oligonucleotide was determined using the following formula: Inhibitory rate (%) = (OD_{CONTROL} - OD_{ASODN}) / OD_{CONTROL} \times 100%.

2.5.4. Xenograft Experiments

A suspension of 2×10^6 HeLa cells in a total volume was injected subcutaneously into the right dorsal flank of the nude mice. Following the engraftment, the mice were assigned into three groups with three kinds of HeLa cells mentioned above treated respectively. The animals were maintained under sterile conditions in individually vented cages. The mice were raised for one month. At the end, the animals were sacrificed and tumors were excised.

2.6. Statistics

Statistics were calculated with the SPSS 12.0 software package. The chi-square test was applied for enumeration data. Analysis of variance (ANOVA) was applied for comparison of the means of two or multiple groups of measurements, and the Student-Newman-Keuls (SNK) test was used for further

group comparison. For all of the analyses, a *P*-value <0.05 was considered statistically significant.

3. Results

3.1. Analysis of Replication in Vivo

The nuclei in duplicate present green fluorescent as Figure 1 A (a) showed; after Propidium Iodide (PI) redyeing, the nuclei were red (b in Figure 1). The total of 300 to 400 nuclei were counted to determine the percentage of replicating nuclei. The results were that the percentage of replicating nuclei was $40.13 \pm 1.02\%$ in HeLa-M cells, which was much higher than $20.54 \pm 0.52\%$ in HeLa cells or $21.23 \pm 0.63\%$ in HeLa-C cells. As a result, the DNA replicating ability of HeLa-M was stronger than the other two groups (n=3, **P*<0.05 vs the other two groups). There was a higher percentage of replicating nuclei in the transfected pCMV/nuc/M-CSF HeLa cells (HeLa-M) compared with the other two groups (n = 3, *P*<0.05, Figure 1B).




Figure 1. The intracellular DNA replicating ability of the three groups.

A) The intracellular DNA replication by BrdU labeling.

a: Replicating nuclei; b: Nuclei (PI after stained); c: The merged of the two ahead ($\times 400$).

B) The percentage of replicating nuclei in the three groups. **P*<0.05 vs the other two groups (n=3);

HeLa: untransfected HeLa cells; HeLa-C: transfected pCMV/myc/nuc HeLa cells; HeLa-M: transfected pCMV/nuc/M-CSF HeLa cells.

3.2. Analysis of Replication *in Vitro* Using a Cell-Free DNA System

To identify whether M-CSF could affect the initiation or elongation stage of DNA replication or not, a cell-free DNA

replication system was used *in vitro*. The cells were synchronized at stage G1/S using a thymidine double-block and verified by flow cytometry. Then, the cells in stage G1 and S were obtained (Table 1).

Table 1. Statistical results of cell synchronization blocked doubly by Thymidine for different time. ($\bar{x} \pm s$, %).

cell cycle	0h	1h	3h	5h	7h	9h
G1	95.60±1.27	96.25±1.48*	94.35±1.91	1.30±0.71	1.25±0.07	0.09±0.85
G2/M	1.50±0.57	1.90±1.13	0.45±0.36	0.40±0.14	0.00±0.00	62.00±8.48
S	2.95±0.64	1.85±2.62	5.20±2.27	98.35±0.49	98.75±0.07#	37.10±9.33

*: Release of the thymidine double-block for 1 h yielded 96.25% of the cells in stage G1;
#: Release of the thymidine double-block for 7 h yielded 98.75% of the cells in stage S.

The total of 300 to 400 nuclei were counted to determine the percentage of replicating nuclei. The results showed that both in phase G1 and S, the percentage of replicating nuclei in the HeLa-M group was higher than that in the other two groups (n = 3, *P*<0.05, Figure 2A and B).

3.3. Effect of Nuclear M-CSF on the Cell Proliferation of HeLa Cells *in Vitro* and *in Vivo*

The M-CSF-transfected HeLa cells had cut down doubling time (33.38±0.19h) than either pCMV/nuc/myc-transfected HeLa cells (47.92±0.22h) or untransfected HeLa cells (47.16±0.23h) (n=3, **P*<0.05 vs the other two groups, Table 2).

Table 2. Effect of nM-CSF on the doubling time of HeLa cells. ($\bar{x} \pm s$, n=3).

Time	HeLa	HeLa-C	HeLa-M
24h	39 000±16	41 000±23	65 000±17
48h	55 500±20	58 000±21	107 000±29
Doubling time (h)	47.16±0.23	47.92±0.22	33.38±0.19*

HeLa: untransfected HeLa cells; HeLa-C: pCMV/nuc/myc-transfected HeLa cells; HeLa-M: pCMV/nuc/M-CSF-transfected HeLa cells.

The proliferation ability of transfected pCMV/nuc/M-CSF HeLa cells was more significantly augmented than either pCMV/nuc/myc transfected HeLa cells or the untransfected cells by MTT assay (Figure 2A). What's more, M-CSF-specific antisense oligonucleotide significantly inhibited the proliferation of the M-CSF-transfected cells in a concentration-dependent manner (Figure 2B) but had little effect on the other two groups. These results suggested M-CSF expressed in nuclei could promote the cell proliferation of HeLa cells *in vitro*.





Figure 2. DNA replication *in vitro* by using mammalian cell-free DNA replication system.

The percentage of replicating nuclei in HeLa-M cells was much higher than that in HeLa cells or HeLa-C cells in Stage G1 or Stage S (n = 3, **P*<0.05 vs the other two groups).

A) The percentage of replication nuclei in stage G1. B) The percentage of replication nuclei in stage S.

HeLa: untransfected HeLa cells; HeLa-C: transfected pCMV/myc/nuc HeLa cells; HeLa-M: transfected pCMV/nuc/M-CSF HeLa cells.



A




Figure 3. Effect of nuclear M-CSF on the cell proliferation of HeLa cells.

A) Effect of M-CSF on the viability of HeLa cells by MTT assay. The proliferation ability of transfected pCMV/nuc/M-CSF HeLa cells was more significantly augmented than either pCMV/nuc/myc transfected HeLa cells or the untransfected cells ($n=3$, $*P<0.05$ vs the other two groups). B) Effect of M-CSF-specific antisense oligonucleotide on the viability of pCMV/nuc/M-CSF-transfected HeLa cells. M-CSF-specific antisense oligonucleotide significantly inhibited the proliferation of the M-CSF-transfected cells in a concentration-dependent manner ($n=3$, $*P<0.05$ vs the other two groups), but had little effect on the other two groups. HeLa: untransfected HeLa cells; HeLa-C: pCMV/nuc/myc-transfected HeLa cells; HeLa-M: pCMV/nuc/M-CSF-transfected HeLa cells.


When the cells were injected subcutaneously into the nude mice, the results could be seen that the xenografts formation time of the group of pCMV/nuc/M-CSF transfected HeLa cells vaccinated was earlier and the tumor size and weight were increased obviously compared with the group of empty plasmid transfected or untransfected HeLa cells. The difference was statistically significant ($P<0.05$). The time to tumor of the group of pCMV/nuc/M-CSF transfected HeLa cells vaccinated was earlier and the tumor weight was increased obviously than the group of empty plasmid transfected or untransfected HeLa cells, the difference was statistically significant ($P<0.05$). It indicated that nuclear M-CSF transfected in HeLa cells could promote the growth and weight of xenograft tumors *in vivo* (Table 3 and Figure 4). All above showed nuclear M-CSF could accelerate the cell proliferation of HeLa cells both *in vitro* and *in vivo*.

Table 3. Effect of M-CSF on the time to tumor and tumor weight of HeLa cell xenografts in nude mice.

Group	animals	Average Time to Tumor (h)	Average Tumor Weight (mg)
HeLa	8	52.25±7.83	3112.21±135.37
HeLa-C	8	51.49±9.21	3218.46±201.52
HeLa-M	8	43.26±6.34*	5293.38±319.36*

*: $P<0.05$, vs the value of the groups including HeLa and HeLa-C cells. ($\bar{x} \pm s$).

HeLa: untransfected HeLa cells; HeLa-C: pCMV/nuc/myc-transfected HeLa cells; HeLa-M: pCMV/nuc/M-CSF-transfected HeLa cells.



*: $P<0.05$, vs the value of the groups including HeLa and HeLa-C cells.

Figure 4. Effect of M-CSF on the tumor size of HeLa cell xenografts in nude mice.

The tumor size of the group of pCMV/nuc/M-CSF transfected HeLa cells vaccinated was increased obviously than the group of empty plasmid transfected or untransfected HeLa cells, the difference was statistically significant ($P<0.05$). HeLa: untransfected HeLa cells; HeLa-C: pCMV/nuc/myc-transfected HeLa cells; HeLa-M: pCMV/nuc/M-CSF-transfected HeLa cells.

4. Discussion

M-CSF is an important cytokine involved in cellular signalling [21, 22]. Commonly, M-CSF secreted by cells, binds to its transmembrane receptor which leads to the transduction of the signal onto the target cell; then the M-CSF-receptor complex is internalized after accomplishing its function and degraded; therefore, M-CSF is usually not found in the cells. However, recent studies have shown that M-CSF can be expressed at a high level in the cytoplasm and nuclei of some kinds of malignant tumors [23-25]. The process is associated with enhanced tumor cells' movement and invasion, resulting in an unfavorable prognosis, which suggests that intracellular expression of M-CSF may have some specific action.

Our preliminary experiments indicated that M-CSF was expressed in HeLa cells at a low level in the cytoplasm but not seen in the nuclei, which was consistent with the literature [12]. To explore the regulation of nuclear M-CSF (nM-CSF) on the proliferation of HeLa cells, pCMV/nuc/M-CSF vectors were constructed and transfected into HeLa nuclei. The results from western blot and indirect immunofluorescence showed that M-CSF protein was expressed at a higher level and localized to the nuclei in M-CSF-transfected HeLa cells compared with either pCMV/myc/nuc transfected HeLa cells or the untransfected HeLa cells [18]. What is the effect and mechanism of nM-CSF? Then, we analyzed the effect of nM-CSF on the proliferation of HeLa cells. M-CSF-transfected HeLa cells had cut down doubling time and more significantly augmented reproductive activity

than the controlled HeLa cells (Table. 2). What's more, M-CSF-specific antisense oligonucleotide significantly inhibited the proliferation of the M-CSF-transfected cells in a concentration-dependent manner, but had little effect on the other two groups (Figure 3). Above all showed nM-CSF could accelerate the cell proliferation of HeLa cells *in vitro*. When the cells were injected subcutaneously into the nude mice, the results showed that the xenografts formation time of the group of pCMV/nuc/M-CSF transfected HeLa cells vaccinated was earlier and the tumor size and weight were increased obviously than the group of empty plasmid transfected or untransfected HeLa cells (Table. 3 and Figure 4). It indicated that nuclear M-CSF transfected in HeLa cells could promote the growth and weight of xenograft tumors *in vivo*. So, nM-CSF could promote the cell proliferation ability of HeLa cells both *in vitro* and *in vivo*.

Cell proliferation is a complex and orderly process affected by many kinds of factors rigorously regulated. DNA replication is one of many important events in cell activities such as cell proliferation. In the process of cell division, only through the replication can genetic information contained in the parental cells be transmitted to offspring cells. After pCMV/nuc/M-CSF vectors were transfected into HeLa nuclei, DNA replication was assessed *in vivo* by BrdU and *in vitro* by using mammalian cell-free DNA replication system. The results showed that there was a higher percentage of replicating nuclei in the transfected pCMV/nuc/M-CSF HeLa cells both in phase G1 and S (Table. 1 and Figure 1 and 2).

Combining with the previous results in our study that M-CSF isolated from human leukemic cell J6-1 and HL-60 nuclei could combine with DNA, one of the non-receptor target molecules of M-CSF named MCM7 using yeast two-hybrid system from HL-60 cellular cDNA library. MCM7 is a member of MCMs. When DNA replication is initiated, MCMs are released from the chromatin. During the S-phase and until mitosis, MCMs are found unbound to replication precursors, which ensures that DNA replication happens only once during each cell cycle [26]. It has DNA helicase activity as a (MCM4/6/7)₂ dimer, and interacts with Cdc45 to recruit DNA polymerase α to the replication origin. As a result, the replication is successfully initiated [27]. Next, we would figure out the interaction between M-CSF and MCM7. Transfected M-CSF might accelerate the cell proliferation via the interaction with MCM7.

5. Conclusion

Therefore, the conclusion was that nM-CSF could accelerate the proliferation of HeLa cells especially in DNA replication.

Acknowledgements

This work was supported by a grant from the National Natural Science Foundation of China (30270684, 81541163), the Natural Science Youth Foundation of Hunan Province

(09JJ3060, 2015JJ3101), the Open Fund Based on Innovation Platform of Hunan Provincial Education Department (15K111), Training project of Hunan Province Cooperative innovation Center for Molecular Target New Drug Study (2014-405) and the construct program of the key discipline in Hunan province.

References

- [1] Kasamatsu E, Cubilla AL, Alemany L, *et al.* Type-specific human papillomavirus distribution in invasive cervical carcinomas in Paraguay. A study of 432 cases. *J Med Virol*, 2012, 84: 1628~1635.
- [2] Pandey S, Chandravati. Autophagy in cervical cancer: an emerging therapeutic target. *Asian Pac J Cancer Prev*, 2012, 13: 4867~4871.
- [3] Ławicki S, Będkowska GE, Gacuta-Szumarska E, *et al.* Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. *Folia Histochem Cytobiol*, 2012, 50: 213~219.
- [4] Beirão BC, Raposo T, Pang LY, *et al.* Canine mammary cancer cells direct macrophages toward an intermediate activation state between M1/M2. *BMC Vet Res*, 2015, 11: 151.
- [5] Bellora F, Castriconi R, Doni A, *et al.* M-CSF induces the expression of a membrane-bound form of IL-18 in a subset of human monocytes differentiating *in vitro* toward macrophages. *Eur J Immunol*, 2012, 42: 1618~1626.
- [6] Liu W, Xu GZ, Jiang CH, *et al.* Expression of macrophage colony-stimulating factor (M-CSF) and its receptor in streptozotocin-induced diabetic rats. *Curr Eye Res*, 2009, 34: 123~133.
- [7] Itoh K, Udagawa N, Matsuzaki K, *et al.* Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. *J Bone Miner Res*, 2000, 15: 1766~1775.
- [8] Booker BE, Clark RS, Pellom ST, *et al.* Interleukin-34 induces monocytic-like differentiation in leukemia cell lines. *Int J Biochem Mol Biol*, 2015; 6 (1): 1~16.
- [9] Ławicki S, Mroczko B, Omyła J, *et al.* Macrophage colony-stimulating factor (M-CSF) as a candidate for the tumor marker of breast cancer. *Pol Arch Med Wewn* 2003, 109: 597~602.
- [10] Lawicki S, Bedkowska E, Gacuta-Szumarska E, *et al.* The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients. *Pol Merkur Lekarski*, 2008, 25: 38~42.
- [11] Espinosa I, Catusas L, D' Angelo E, *et al.* Stromal signatures in endometrioid endometrial carcinomas. *Mod Pathol*, 2014, 27 (4): 631~639.
- [12] Kirma N, Hammes LS, Liu YG, *et al.* Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. *Cancer Res*, 2007, 67: 1918~1926.

- [13] Powell JA, Thomas D, Barry EF, *et al.* Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. *Blood*, 2009, 114 (23): 4859~4870.
- [14] Bourguignon LY, Singleton PA, Zhu H, *et al.* Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. *J Biol Chem*, 2003, 278: 29420~29434.
- [15] Newa M, Bhandari KH, Tang L, *et al.* Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug. *Pharm Res*, 2011, 28: 1131~1143.
- [16] Bedkowska GE, Ławicki S, Szmitkowski M. Molecular markers of carcinogenesis in the diagnostics of cervical cancer. *Postepy Hig Med Dosw (Online)*, 2009, 63: 99~105.
- [17] Mancino AT, Klimberg VS, Yamamoto M, *et al.* Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. *J Surg Res* 2001, 100: 18-24.
- [18] Tu J, Teng SJ, Zhang XH, *et al.* Construction and identification of M-CSF stably expressed in the cellular nuclear. *Chinese Journal of Pathophysiology*, 2009, 25: 622~624.
- [19] Cao ZY, Zhang B, Rao Q, *et al.* Effects of nuclear-presenting -macrophage colony-stimulating factor on the process of malignancy. *Int J Hematol*, 2003, 78: 87~89.
- [20] Darzynkiewicz Z, Halicka HD, Zhao H, *et al.* Cell synchronization by inhibitors of DNA replication induces replication stress and DNA damage response: analysis by flow cytometry. *Methods Mol Biol*, 2011, 761: 85~96.
- [21] Smith AM, Gibbons HM, Oldfield RL, *et al.* M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia. *J Neuroinflammation*, 2013, 10: 85.
- [22] Curry JM, Eubank TD, Roberts RD, *et al.* M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis *in vivo*. *PLoS One*, 2008, 3: e3405.
- [23] Johansson AS, Lidén J, Okret S, *et al.* Effects of ethanol on cytokine generation and NFkappaB activity in human lung epithelial cell. *Biochem Pharmacol*, 2005, 70: 545~551.
- [24] Lu SY, Wan HC, Li M, *et al.* Subcellular localization of Mitf in monocytic cells. *Histochem Cell Biol*, 2010, 133: 651~658.
- [25] Li X, Vradii D, Gutierrez S, *et al.* Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU. 1. *J Cell Biochem*, 2005, 96: 795~809.
- [26] Tuteja N, Tran NQ, Dang HQ, *et al.* Plant MCM proteins: role in DNA replication and beyond. *Plant Mol Biol*, 2011, 77: 537~545.
- [27] Bauerschmidt C, Pollok S, Kremmer E, *et al.* Interactions of human Cdc45 with the Mcm2-7 complex, the GINS complex, and DNA polymerases delta and epsilon during S phase. *Genes Cells*, 2007, 12: 745~758.